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switched its focus away from vaccines 
that induce sterilizing immunity (still the 
ultimate goal) toward those that con-
trol viral load after infection and thus 
reduce secondary transmission (  7  –  11  ). 
This shift was prompted by data show-
ing that T cell  –  mediated immunity 
was critical for resistance to immuno-
defi  ciency viruses. For example, depletion 
of CD8 
+   cells in simian immuno-
defi  ciency virus (SIV)-infected macaques 
led to a resurgence of viral load (  12  ), 
and in HIV-infected individuals known 
as   “  elite controllers,  ”   the control of viral 
load was associated with potent and broad 
cellular immune responses (  13, 14  ). 
        The pathway to an HIV vaccine has 
never been considered easy or straight-
forward (  1, 2  ). The challenges involved 
in developing a successful vaccine have 
accumulated from the time of the fi  rst 
clinical trials of the Microgenesis vac-
cine to the highly publicized Vaxgen 
trial (  1, 3, 4  ). These HIV envelope  –
  based vaccines were aimed at inducing 
neutralizing antibody responses, as sev-
eral groups had shown that passive 
transfer of large amounts of neutral  izing 
antibodies could protect primates against 
infection. Unfortunately, these fi  rst tri-
als failed in large part because inducing 
neutralizing antibodies is a daunting task 
at which more than one group has failed 
(  5  ). Other reasons for these failures in-
clude the genetic variability of the viral 
envelope proteins, which allows the vi-
rus to escape neutralizing antibodies, and 
the diffi   culty in identifying immuno-
gens and immunization platforms that 
consistently induce antibodies that can 
neutralize several HIV clades (  6  ). 
  A shift in focus 
  In light of the diffi   culties in eliciting 
neutralizing antibodies, the fi  eld  has 
The world of human immunodefi  ciency virus (HIV) vaccines has suffered a 
baffl  ing setback. The fi  rst trial of a vaccine designed to elicit strong cellular 
immunity has shown no protection against infection. More alarmingly, the 
vaccine appeared to increase the rate of HIV infection in individuals with 
prior immunity against the adenovirus vector used in the vaccine. A new 
study in this issue suggests that a different vaccine approach  —  using a DNA 
prime/poxvirus boost strategy  —  induces polyfunctional immune responses to 
an HIV immunogen. The disappointing results of the recent vaccine trial 
suggest that a more thorough assessment of vaccine-induced immune 
responses is urgently needed, and that more emphasis should be placed on 
primate models before effi  cacy trials are undertaken.
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The STEP vaccine trial failed to pro-
tect Ad5-seronegative individuals 
against infection and may even have 
enhanced infection in vaccinees with 
prior immunity to adenoviruses.
These fi  ndings have helped move the 
fi  eld toward the development of vac-
cines designed to elicit strong cellular 
immunity (  15  ). 
  One approach to generating robust 
T cell responses is to express HIV anti-
gens in replication-defective recombinant 
adenoviral vaccines (  16  ). These vectors 
elicit protection in some primate mod-
els of HIV infection and induce detect-
able CD8 
+   T cell responses in humans, 
suggesting that this approach could help 
limit viral load and disease progression 
(  16  –  19  ). But this approach is not with-
out its problems. There have been 
several concerns about the use of recom-
binant adenovirus serotype 5 (rAD5) as 
a vaccine vector, including preexisting 
vector-specifi   c immunity and uncer-
tainty about whether these vectors can 
induce long-lasting, broad, and pro-
tective immune responses (  20  –  22  ). The 
scientifi  c community has recently learned 
that the STEP HIV vaccine trial, which 
used an rAd5-based vaccine developed 
by Merck, failed to protect Ad5-sero-
negative individuals against infection 
and may even have enhanced infection 
in vaccinees with prior immunity to 
adenoviruses (  23  –  26  ). In this issue, 
Harari et al. (p. 63            ; reference   27  ) report 
on an alternative heterologous prime-
boost strategy in which DNA priming 
improved the immunogenicity of a re-
combinant viral vector, in this case the 
vaccinia virus NYVAC (  27  ). In this 
Commentary, I will discuss the STEP 
trial and the new report from Harari 
et al. from the perspective of some-
one engaged in research on human T 
cell function and the immune moni-
toring of vaccination protocols. 
  Refl  ections on the STEP trial 
  The STEP trial involved the immuni-
zation of almost 3,000 healthy uninfected 
volunteers with three rAD5 vectors, 
each expressing an HIV gene: Ad5-gag, 
Ad5-pol, and Ad5-Nef (http://www
.hvtn.org/media/pr/step111307.html). 
This proof-of-concept trial was intended 
to test the capacity of the vaccine to 
reduce infection and to reduce the viral 
load (or   “  set point  ”  ) in vaccinated 
individuals who nevertheless became 
infected. Each individual in the trial re-
ceived three injections of the three T
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Phase I and II studies (see http://www
.hvtn.org/science/1107.html for the 
recently released STEP trial results) as 
measured mostly by a single parameter: 
the IFN-     ELISPOT assay. The rAd 
vaccine also induced long-lasting, multi-
functional responses as monitored by poly-
chromatic fl  ow cytometry (http://www
.hvtn.org/fgm/1107slides/McElrath.pdf). 
Indeed, after homologous prime-boost 
immunization with a replication-defec-
tive adenovirus-based vaccine, a ma-
jority of responders had HIV-specifi  c 
CD8 
+   T lymphocytes that were capable 
of producing CD107, macrophage in-
fl  ammatory protein 1   , IFN-   , and TNF, 
and antigen-specifi  c CD4 
+   T cells that 
were able to produce IFN-    , interleukin 
(IL)-2, and TNF (Casimiro, D., personal 
communication). The CD8 T cell re-
sponses to HIV antigens, however, were 
not particularly broad. A median of three 
peptide pools, each consisting of over-
lapping 9  –  amino acid peptides spanning 
a 16  –  amino acid region of gag, nef, or 
pol, was recognized by vaccinated sub-
jects (Casimiro, D., personal communi-
cation). Thus, by all accounts, the STEP 
vaccine was safe, immunogenic (by the 
aforementioned criteria), and induced 
some level of protection in primate stud-
ies. Although some may have predicted 
disappointing results based on the rela-
tively weak protection in macaques and 
the lack of a broad T cell response, no 
one could have predicted the correla-
tion between preexisting vector-specifi  c 
immunity and an increase in suscepti-
bility to infection  —  a result that lead to 
the immediate halting of both the STEP 
and Phambilli trials. 
  The new study by Harari et al. clearly 
shows that the DNA/NYVAC prime-
boost regimen induces HIV-specifi  c 
CD4 
+   and CD8 
+   T cell responses (  27  ). 
In this regimen, DNA priming was es-
sential for the induction of a strong re-
sponse to the recombinant virus. The T 
susceptibility to HIV infection in vacci-
nated subjects. Although the statistical 
analysis has not been completed, the 
initial results show that vaccinated sub-
jects who had high titers of antibodies 
against adenovirus tended to have a higher 
incidence of HIV infection than those 
without anti-adenovirus antibodies. One 
possible explanation for this outcome is 
that the presence of both antibody and 
virus could lead to the activation of T 
cells, thus providing an environment that 
favors HIV replication. 
  These results raise several critical 
questions. Was the failure of this Ad5-
based trial attributable to something spe-
cifi  c about the Merck rAd5 vector, or 
would all rAd vectors face similar prob-
lems? Of note, the Merck rAD5 vector 
is missing only one adenovirus protein 
(E1) and thus expresses more viral genes 
than other adenovirus vectors. The vec-
tor used by National Institutes of Health ’  s 
Vaccine Research Center, for example, 
lacks both the E1 and E3 protein. Mini-
mizing the number of viral genes in a 
vaccine vector helps strip the virus of its 
natural ability to evade the immune sys-
tem. The STEP trial also included three 
shots of the vaccine, and it is unclear 
whether the increased rate of infection 
would have occurred if only a single shot 
of rAd5-based vaccine had been used. 
The fundamental question, however, is 
whether the problem was with the spe-
cifi   c vector or immunization regimen 
used in the STEP trial, or whether there 
is a more general danger of using viral 
vectors to immunize against HIV. In 
light of the immunomodulatory prop-
erties of viruses and attenuated viral vec-
tors, we should systematically investigate 
vector-specifi  c immunity and, more im-
portantly, its impact on qualitative and 
quantitative parameters of the HIV-spe-
cifi  c immune response. One cannot ex-
clude the possibility that the rAd5 vector 
and the immune response to the vector 
(whether innate or adaptive) prevented 
the full development of an HIV-specifi  c 
immune response. 
  Immune responses to vaccines: quality 
versus quantity 
  The Merck candidate vaccine showed 
good HIV-specifi  c immunogenicity in 
rAD5 vectors, with the last two injec-
tions spaced 6 months apart. The same 
vaccine was being administered in 
South Africa to 3,000 individuals in the 
Phambilli trial when the initial results of 
the STEP trial were made public. 
  The path to the development of the 
STEP trial included 12 Phase I trials 
with more than 1,300 volunteers, which 
showed that the vaccine was safe and 
immunogenic as measured by a standard-
ized interferon (IFN)-     enzyme-linked 
immunospot (ELISPOT) assay. Experi-
ments in primates also showed some 
protection. Immunization with the de-
fective rAD5 vector followed by chal-
lenge with a hybrid SHIV (SIV with an 
HIV envelope) lead to a 1  –  3 log de-
crease in viral load (  16  ). However, these 
experiments were performed on only a 
limited number of macaques. And a more 
stringent challenge with the SIV mac239 
strain resulted in a more modest decrease 
of viral load (    1 log, leaving an average 
of 10 
5   copies of RNA/ml plasma in 
vaccinated animals) (  17, 28  ). In addi-
tion, this immunization strategy was ef-
fective only in monkeys carrying a specifi  c 
human histocompatibility leukocyte 
antigen (HLA) allele known to present a 
dominant epitope from the gag protein. 
Thus, the Merck vaccine had limited 
effi   cacy in a stringent primate model. 
  The foremost issue facing any rAd5-
based vaccine is the high prevalence of 
adenovirus-specifi  c antibodies as a result 
of prior exposure to the virus, particu-
larly in sub-Saharan Africa. Adenovirus 
vectors, and many other viral vectors 
currently used in HIV vaccines, will in-
duce a rapid memory immune response 
against the vector. The resulting elimi-
nation of the vector was anticipated to be 
an impediment to the development of a 
T cell response against the inserted anti-
gen. What was completely unexpected, 
however, was the possibility that previ-
ous adenovirus infection might enhance 
What was completely unexpected, 
however, was the possibility that 
previous adenovirus infection might 
enhance susceptibility to HIV infec-
tion in vaccinated subjects.
We should reflect on whether the 
assays we are currently using to 
guide vaccine development should be 
expanded to include additional sur-
rogate markers of efficacy.JEM VOL. 205, January 21, 2008  9
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TNF. Hence, at fi  rst glance it appears 
that pox and rAD5 vectors elicit over-
lapping but qualitatively diff  erent Th1 
responses. Current immune-  monitoring 
strategies are focused on measuring ef-
fector T cell responses. They do not, 
however, measure memory and its re-
newal or persistence, despite the fact that 
absolute numbers of memory T cells and, 
in particular, central memory T cells 
have been associated with protection in 
primate models (  9  ). Nor do the current 
strategies assess other immune parame-
ters, such as Th2 cytokines and innate 
immune responses. In light of the STEP 
trial outcome, one has to keep an open 
mind on the kind of polyfunctional-
ity that will provide protection. The 
term polyfunctionality might also imply 
more than just the induction of CD8 
+   
and CD4 
+   cells that produce multiple 
cytokines; it could also refl  ect an inte-
grated immune response that includes 
diff  erent types of T cells (Th1 and Th2), 
B cells, and other innate immune cells, 
including dendritic cells and natural 
killer (NK) cells. Our current assays also 
do not allow us to evaluate the homing 
of T cells to mucosal sites, the primary 
site of HIV infection. 
  How should we measure the success 
of a vaccine? Successful, well-tested 
vaccines such as the smallpox, hepatitis 
A, and yellow fever vaccines all elicit 
broad integrated responses that encom-
pass all eff  ector arms of immune response, 
including innate (Toll-like receptor  –
  mediated) responses, NK cell responses, 
and Th1/Th2 responses (  37  –  40  ). With 
the knowledge that the innate immune 
response infl  uences both qualitative and 
quantitative features of adaptive immu-
nity, one should make every attempt to 
identify innate responses that correlate 
with protection (  38  ). Information is cur-
rently lacking on the innate responses 
elicited by the diff  erent vectors, including 
the results of the STEP trial. In addition, 
the DNA-priming step appears to en-
hance the immune response against 
the poxvirus, as it also does with other 
vectors, including adenoviruses (  33  –  36  ). 
Hence, the DNA prime NYVAC –  boost 
strategy not only might bypass the re-
quirement for multiple booster injec-
tions with viral vector, but it might also 
favorably modulate the immune response 
against the immunogen. Finally, the 
immunogenicty data obtained with the 
DNA/poxvirus strategy show that this 
vector combination can induce potent, 
multifunctional immune responses, in-
cluding a large fraction of IL-2  –  producing 
cells, which are often endowed with 
superior memory functions. 
  In response to the STEP failure, how-
ever, it is important to continue to 
research the criteria that best predict 
protective T cell immunity against patho-
gens. It must now be determined whether 
the potential improvements aff  orded by 
DNA prime virus  –  boost regimens war-
rant large-scale clinical studies to evaluate 
protective immunity. More importantly, 
we should refl  ect on whether the assays 
we are currently using to guide vac-
cine development should be expanded 
to include additional surrogate markers 
of effi   cacy, or whether they need only 
provide a simple indicator of immuno-
genicity. The fi  eld should quickly de-
velop assays that will help in predicting 
the development of protective immu-
nity in response to vaccines. 
  Polyfunctionality and its scope 
  Polyfunctional T helper (Th)1 cells that 
make higher levels of cytokines on an 
individual cell basis (e.g., as assessed by 
mean fl  uorescence intensity for IFN-     
staining) have been associated with pro-
tection in vaccine trials against other 
microbes as well as in HIV-infected elite 
controllers (  31, 32  ). Both adenovirus-
based vaccines and the DNA/NYVAC 
vaccine trigger T cells that produce at 
least three diff  erent cytokines in response 
to the HIV immunogen. The DNA/
NYVAC vaccine elicited a greater fre-
quency of CD8 cells and Th1 cells se-
creting IL-2, TNF, and IFN-    , whereas 
the rAD-based vaccines typically elic-
ited little IL-2 and mostly IFN-     and 
cell responses were also polyfunctional; 
nearly 50% of the HIV-specifi  c CD4 
+   
and CD8 
+   T cells induced in vaccinated 
subjects produced more than three cy-
tokines. It is also interesting to note that 
this regimen induced strong T cell pro-
liferation and, more importantly, robust 
production of the T cell growth factor 
IL-2 by HIV-specifi  c CD4 
+   and CD8 
+   
cells (  29  ). These responses were also 
persistent, as some T cell responses were 
still detectable after 96 weeks (Pantaleo, 
G., personal communication). A big ef-
fort is now being made to standardize 
immune-monitoring assays in humans 
and in preclinical models, but it is cur-
rently diffi   cult to compare the relative 
immunogenicity of two vectors outside 
of a single trial where the two vac-
cines are compared head-to-head using 
a common, standardized set of assays to 
monitor the resulting immune response. 
Alternatively, immune responses from 
both trials should be tested in a single 
assay platform. 
  One notable diff  erence between the 
vaccines used in the STEP trial and by 
Harari et al. was the detection in the lat-
ter study of higher frequencies of CD4 
+   
and CD8 
+   T cells producing a high level 
of IL-2 or both IL-2 and IFN-    . These 
dual-producing cells have previously 
been associated with better control of 
viral load after vaccination and in natu-
ral history studies (  30  ). Polyfunctional T 
cell responses have also been associated 
with protection against   Leishmania major   
infection (  31  ) and are a feature of im-
mune responses in HIV-infected elite 
controllers (  32  ). Moreover, while rAd5-
based vaccines elicit strong CD8 responses 
to gag, the DNA/NYVAC leads to the 
development of strong env-specifi  c re-
sponses, whereas gag-specifi  c responses 
are poor. Of note, the rAd5 vaccine 
tested in the STEP trial did not include 
env constructs. 
  The DNA/poxvirus immunization 
strategy may thus provide a promising 
alternative to adenoviral vector  –  based 
approaches. This strategy is also advan-
tageous in that most individuals born 
after 1974 have not been immunized 
against smallpox and hence will have 
little preexisting immunity to these vi-
ruses  —  an important consideration given 
The vector-specific immune response 
and the immunomodulatory func-
tion of vector-encoded proteins 
could compete or bias HIV-specific 
responses.10 SYSTEMS BIOLOGY FOR HIV VACCINE DEVELOPMENT | Sekaly
responses are still far from the clinic. 
Hence, pursuing the T cell approach is 
a viable alternative, provided we can 
optimize the vaccines and develop a co-
ordinated strategy to evaluate immune 
responses in greater depth. The tools to 
do this are emerging through initiatives 
like the Global Enterprise for an HIV 
vaccine. As we are still far from under-
standing the ingredients required for ef-
fective vaccines, attempts to better 
understand the components of the im-
mune response to licensed, effi   cacious 
vaccines should be a research priority. 
This research will help defi  ne the elu-
sive correlates of T cell immunity to 
vaccines in humans. 
  The author would like to acknowledge the 
contributions of Ralph Steinman, Robert Seder, Larry 
Corey, Danilo Casimiro, Rafi   Ahmed, and Giuseppe 
Pantaleo for helpful discussions and sharing of 
unpublished data. 
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